BEDMINSTER, N.J. -- Bioject Medical Technologies, Inc., a leading developer of needle-free drug delivery systems, today announced that it has entered into a development agreement with a leading European biotechnology company whereby Bioject will develop a new needle-free drug delivery system which utilizes the companys B2000 technology exclusively for an undisclosed indication. Terms of the agreement include upfront license and development fees of $550,000 and product development and regulatory milestone payments of approximately $3.5 million to $4 million. The agreement also provides for transfer pricing and royalty payments upon commercialization of the drug with the newly developed product. Assuming successful development of the product, commercialization is currently anticipated in 2008.
We are very enthusiastic about this partnership for the development of a needle-free delivery system in a market which has never utilized needle-free systems said Jim OShea, chairman, president and CEO of Bioject. This collaboration represents a key strategic transaction for Bioject with a high value-added, injected medication and demonstrates the continuing progress we are making in the expansion of uses for our technology.
The newly developed product will utilize Biojects CO2 powered B-2000 technology, which will be modified for the delivery of a specific proprietary application.
Bioject Medical Technologies Inc., based in Bedminster, N.J., with operations in Portland, Ore., is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on development mutually beneficial agreements with leading pharmaceutical, biotechnology and veterinary companies.
Source: Bioject
“Ongoing Assault”: How HHS Layoffs Have Eviscerated Infection Prevention Support Across the Nation
April 1st 2025Mass layoffs at HHS and CDC have gutted critical infection prevention programs, leaving frontline professionals overwhelmed, under-resourced, and desperate to safeguard public health.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.